Cerus Corporation: Q3 2023 Form 10-Q Summary
Business context and reporting period
Cerus develops and commercializes the INTERCEPT Blood System for pathogen reduction of platelets and plasma, and for cryoprecipitation. The red blood cell system remains in development and has not been commercialized. This Form 10-Q covers the three and nine months ended September 30, 2023; financial statements are unaudited and presented under U.S. GAAP.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Product revenue | $39.8 million | $39.6 million | $109.6 million | $118.0 million |
| Government contract revenue | $7.5 million | $6.8 million | $23.9 million | $19.0 million |
| Total revenue | $47.3 million | $46.3 million | $133.5 million | $137.0 million |
| Gross profit on product revenue | $21.8 million | $21.9 million | $60.4 million | $62.6 million |
| Loss from operations | $(5.2) million | $(7.4) million | $(31.0) million | $(24.1) million |
| Net loss attributable to Cerus | $(7.3) million | $(8.5) million | $(36.2) million | $(29.2) million |
| Loss per share | $(0.04) | $(0.05) | $(0.20) | $(0.17) |
- Product gross margin was 55% in both Q3 2023 and Q3 2022, and 55% for the first nine months of 2023 versus 53% in the prior-year period.
- Research and development expense was $16.8 million in Q3 and $53.4 million for nine months, up 3% and 17%, respectively, primarily from next-generation illuminator development and increased clinical activity.
- Selling, general and administrative expense declined 19% in Q3 to $16.2 million and 3% for nine months to $58.2 million, primarily reflecting reduced headcount and lower stock-based compensation.
- Restructuring charges were $1.6 million in Q3 and $3.7 million for nine months, related to severance and facilities consolidation.
- Interest expense increased to $2.4 million in Q3 and $6.2 million for nine months, reflecting higher interest rates and debt levels.
- Net cash used in operating activities was $28.0 million for nine months, compared with $23.9 million in the prior-year period. Capital expenditures were $4.6 million.
- Cash, cash equivalents and short-term investments totaled $79.0 million at September 30, 2023; including restricted cash, total liquidity was $80.8 million, down from $103.9 million at December 31, 2022.
- Total debt was $78.6 million, including $18.8 million current and $59.8 million non-current. The debt is secured by substantially all company assets, subject to exclusions, and bears primarily floating-rate interest.
- Working capital was $70.8 million, compared with $53.1 million at December 31, 2022, primarily because amended credit facilities shifted debt from current to non-current classification.
Material changes versus the prior comparable period
- Q3 product revenue increased 1%, but nine-month product revenue declined 7%, primarily because U.S. customers reduced disposable platelet kit inventory after the U.S. platelet-kit shelf life was temporarily limited to six months.
- Government contract revenue increased 10% in Q3 and 26% for nine months, driven primarily by BARDA and the Department of Defense contract.
- Nine-month operating loss widened by $6.9 million despite lower SG&A, due mainly to higher R&D and restructuring costs.
- Cash consumption increased year over year, driven by lower sales, inventory purchases and timing of collections and payments. Total inventory increased to $63.9 million from $44.5 million at year-end 2022.
- In March 2023, Cerus amended and restated its term and revolving credit facilities. In September 2023, it borrowed an additional $5.0 million under the term-loan facility. The term loan carried an interest rate of approximately 11.9% at September 30, 2023.
- In June 2023, Cerus initiated a restructuring plan involving a reduction in force and facilities consolidation; approximately 15,000 square feet of office space was no longer used during Q3.
Guidance, outlook, risks and unusual items
- Management expects future product revenue growth from increased market acceptance of INTERCEPT and expansion into additional geographies, but does not provide specific revenue or earnings guidance in the filing.
- Management believes available cash, short-term investments, product receipts and government-contract funding will meet capital requirements for at least the next 12 months. This assessment depends on assumptions regarding revenue, BARDA funding, capital access and spending.
- BARDA had committed up to $185.5 million as of September 30, 2023. Potential total funding was described as up to $270.2 million through September 2026, but additional option periods are discretionary and BARDA may terminate for convenience. The company could be responsible for up to $1.4 million of co-investment if certain options are exercised.
- The red blood cell system faces clinical, manufacturing, supplier, regulatory and CE certification uncertainties. The filing does not provide a clear timetable for certification or commercialization.
- Cerus relies heavily on third parties, including Fresenius as the primary supplier of finished platelet and plasma disposable kits, and has identified sole-source, component-obsolescence, capacity and supply-chain risks. The company is also developing a redesigned illuminator while existing-model components are being phased out.
- Purchase commitments totaled $12.1 million short term and $5.5 million long term at September 30, 2023. Future operating lease payments totaled $21.3 million before imputed interest.
- The company is subject to an ongoing Department of Justice Antitrust Division civil investigative demand received in November 2022 concerning contracting and information-exchange practices. No claim or proceeding had been initiated as of the filing date, but costs and a potentially unfavorable outcome could be material.
- Two customers represented approximately 50% of trade receivables. American Red Cross represented 35% of nine-month product revenue and Établissement Français du Sang represented 13%, highlighting customer concentration.
- The company continues to incur losses and states that it may need additional debt or equity financing. Its at-the-market facility permits sales of up to approximately $96.8 million of common stock, although no shares were sold under the facility during the first nine months of 2023.
- On September 15, 2023, the CFO adopted a Rule 10b5-1 trading arrangement covering sales of up to 45,423 shares through May 10, 2024.
Most important facts for investors to verify
- Whether U.S. platelet-kit shelf-life constraints and customer inventory rebalancing have ended, and whether product revenue is returning to sustained growth.
- Actual operating cash-burn trends, inventory normalization and the duration of the company’s stated liquidity runway.
- Debt covenant compliance, floating-rate exposure, future amortization requirements and the availability of remaining term-loan tranches.
- BARDA option exercises, reimbursement timing, milestone performance and the risk of reduced or terminated funding.
- Timing and likelihood of CE certification and eventual U.S. approval for the red blood cell system.
- Progress and costs associated with the redesigned illuminator, Fresenius capacity expansion and other sole-source supply risks.
- Potential financial, operational or reputational effects of the DOJ antitrust investigation.
- Customer concentration, adoption rates for INTERCEPT and commercialization of IFC through blood-center manufacturing partners.